FDA 483 - Celgene Corporation - September 12, 2012

An FDA inspection of Celgene Corporation in Summit, NJ, revealed significant deficiencies in the conduct and oversight of a clinical investigation. Observations included failures to adhere to the investigational plan and protocols, inadequate study monitoring, and insufficient record-keeping for investigational drug disposition. These issues indicate a lack of control over critical aspects of clinical trial management.